Meeting
2013 ASCO Annual Meeting
The prognostic and predictive impact of genomic grade index (GGI) versus central grade or molecular class in intermediate-risk breast cancer (BC): Results from the EC-Doc trial.
Authors
Oleg Gluz
West German Study Group; Evangelic Hospital Bethesda, Moenchengladbach, Germany
Oleg Gluz , Cornelia Liedtke , Helene P. Peyro Saint Paul , Ulrike Nitz , Ronald E. Kates , Jens Bodo Huober , Arndt Hartmann , Hans Heinrich Kreipe , Enrico Pelz , Ramona Erber , Walther Kuhn , Nadia Harbeck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Cytotoxic Chemotherapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 1092)
DOI
10.1200/jco.2013.31.15_suppl.1092
Abstract #
1092
Poster Bd #
25C
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
The relationship between the change with neoadjuvant chemotherapy in the tumor-infiltrating lymphocyte (TIL) expressions and pathological response in breast cancer patients.
First Author: Ahmet Bilici
Poster
2016 ASCO Annual Meeting
Prognostic impact of 21 Gene Recurrence Score, IHC4, and central grade in high-risk HR+/HER2- early breast cancer (EBC): 5-year results of the prospective Phase III WSG PlanB trial.
First Author: Oleg Gluz
Poster
2016 ASCO Annual Meeting
Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).
First Author: Fabricio Eugenio Racca
Poster
2014 ASCO Annual Meeting
Adjuvant gemcitabine for high-risk breast cancer (BC) patients: Final survival results of the randomized phase III SUCCESS-A study.
First Author: Wolfgang Janni